This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and ChromaDex (CDXC) have performed compared to their sector so far this year.
ChromaDex (CDXC) Reports Break-Even Earnings for Q2
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 100% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 9.37% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
by Zacks Equity Research
ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 136.36% and 15.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 40% and 16.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 6.52% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for ChromaDex (CDXC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why ChromaDex (CDXC) is Poised for a Turnaround After Losing 7.5% in 4 Weeks
by Zacks Equity Research
ChromaDex (CDXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks.com featured highlights Oxford Industries, ChromaDex, UserTesting and TravelCenters of America
by Zacks Equity Research
Oxford Industries, ChromaDex, UserTesting and TravelCenters of America have been highlighted in this Screen of The Week article.
Bet on These 4 Top-Performing Liquid Stocks for Solid Returns
by Vaishali Doshi
Here are four top-ranked liquid stocks, Oxford Industries (OXM), ChromaDex (CDXC), UserTesting (USER) and TravelCenters of America (TA), which investors can add to their portfolio for returns.
ChromaDex (CDXC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 8.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.